

Edge Therapeutics, Inc.  
Form 425  
March 04, 2019

Filed by Edge Therapeutics, Inc.  
pursuant to Rule 425 under the Securities Act of 1933  
and deemed filed under Rule 14a-6(b) of the Securities Exchange Act of 1934  
Subject Company: Edge Therapeutics, Inc.  
Commission File No. 001-37568

**TIME IS SHORT AND YOUR VOTE IS IMPORTANT  
PLEASE VOTE YOUR PROXY TODAY**

March 4, 2019

Dear EDGE Stockholder:

The Special Meeting of Stockholders of Edge Therapeutics, Inc. (“EDGE”) scheduled for March 14, 2019 is rapidly approaching. According to our latest records, we have not received your vote for this important meeting. Your vote is extremely important no matter how many shares you hold.

As previously indicated, EDGE stockholders are being asked to vote on (i) a proposal to approve the issuance of EDGE common stock in connection with the merger, (ii) a proposal to approve a reverse split of EDGE common stock, and (iii) a proposal to approve the amended and restated 2014 EDGE equity incentive plan.

EDGE Reiterates its Support for, and Recommendation that Stockholders Vote in Favor of, the Share Issuance, the Reverse Split and the Equity Incentive Plan Proposals

EDGE Stockholders Will Have a Significant Opportunity To Participate in Potential Growth

The merger with PDS Biotechnology Corporation (“PDS”) will provide existing EDGE stockholders a significant opportunity to participate in the potential growth of the combined company following the merger. We expect that the combined company will be led by an experienced senior management team and a board of directors with representation from each of the current boards of directors of EDGE and PDS.

The EDGE Board Conducted a Thorough and Exhaustive Process

In the course of its evaluation of the merger and the merger agreement among EDGE, Echos Merger Sub, Inc. and PDS, the EDGE Board of Directors (the “EDGE Board”) evaluated over 140 potential merger partners, consulted with EDGE’s executive management, legal counsel and financial advisors, and reviewed and assessed a significant amount of information in reaching its decision to approve the transactions contemplated by the merger agreement.

The EDGE Board Considered a Number of Factors

Such factors included PDS’s proprietary platform, as well as its immunotherapies pipeline, which includes clinical

stage candidates that hold the potential to address sizeable market opportunities, and may provide new medical benefits for patients and returns for investors

After considering the comprehensive diligence review that EDGE management had completed of other prospective transaction partners, the EDGE Board concluded that the merger with PDS would create a publicly traded company focused on advancing its proprietary platform, with its applicability in several cancer markets, as well as its product pipeline, which includes clinical stage candidates that hold the potential to address potential sizeable unmet market opportunities.

---

YOUR VOTE IS IMPORTANT

The reverse stock split proposal will not be approved unless holders of a majority of the outstanding shares of common stock vote "FOR" the proposal. If you fail to vote on the reverse split proposal, the effect will be the same as a vote against the proposal. The EDGE Board unanimously recommends that EDGE stockholders vote FOR each of the above proposals.

Please vote your shares today. Please vote by Internet or telephone in order to participate promptly in the vote. See instructions below.

If you need assistance voting your shares, please call D.F. King & Co., Inc. toll free at (800) 967-5074.

On behalf of the EDGE Board, thank you for your cooperation and continued support.

Sincerely,

/s/ Brian A. Leuthner  
Brian A. Leuthner  
President and Chief Executive Officer

You may use one of the following simple methods to promptly provide your voting instructions:

Vote by Internet – Please access the website listed on your proxy card or voting instruction form and follow the instructions provided.

Vote by Telephone - Please call the toll free number listed on your proxy card or voting instruction form and follow the instructions provided.

Vote by Mail - Mark, sign, date and return your proxy card or voting instruction form and return it in the postage-paid return envelope provided.

---

## Forward-Looking Statements

Statements included herein may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to EDGE’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “seeks,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of EDGE’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond EDGE’s control) as described under the heading “Risk Factors” in EDGE’s filings with the United States Securities and Exchange Commission.

## Additional Information and Where to Find It

In connection with the pending merger with PDS, EDGE has filed relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 that contains a proxy statement/prospectus. Investors may obtain the proxy statement/prospectus, as well as other filings containing information about EDGE, free of charge, from the SEC’s Web site ([www.sec.gov](http://www.sec.gov)). In addition, investors and securityholders may obtain free copies of the documents filed with the SEC by EDGE by directing a written request to: Edge Therapeutics, Inc. 300 Connell Drive #4000, Berkeley Heights, NJ 07922, Attention: Corporate Secretary or delivered via e-mail to [investors@edgetherapeutics.com](mailto:investors@edgetherapeutics.com). Investors and securityholders are urged to read the proxy statement, prospectus and the other relevant materials before making any voting or investment decision with respect to the merger.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

## Participants in the Solicitation

EDGE and PDS and their respective directors and executive officers and certain of their other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of EDGE in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger will be included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of EDGE is also included in EDGE’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 21, 2019. These documents are available free of charge from the sources indicated above.

---